Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The management of thyroid cancer patients with suspicion of recurrent disease based on
rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body
scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected.
The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT
may allow better identification of recurrent disease, thus allowing for more patients to be
treated with I-131 as a curative attempt.